Rapamycin was the first drug definitively shown to extend lifespan in mammals—but there’s room for improvement. In this episode, Joan Mannick tells us how Tornado Tx is developing potent rapalogs to treat age-related disease.
🎧 player.captivate.fm/episode/bb9d9d…
Mikhail V. Blagosklonny, MD, PhD I would consider re-wording the last sentence in the opening paragraph such that it announces the intentions for the rest of the article.
E.g. 'In this article we will explore existing data which suggests rapalogs have the ability to delay or prevent cancer'.
Its gratifying seeing our paper picked up by the news. Thank you Anna Drangowska-Way for this well-written article. Lifespan.IO. #rapalogs #rapamycin #mTOR #longevity #ai #drugdiscovery
lifespan.io/news/using-ai-…
Introducing Amy Yadev as one of our 2023 AGE Early Career Scholars! Amy is a postbaccalaureate researcher at UW–Madison. Her research focus is testing rapalogs in insulin-resistant older adults. #AGEScholars #AGETC
Dr. Evelyne Yehudit Bischof ARDD Meeting Nature Medicine Thomas Rando Stanford Center on Longevity Michael Ringel, JD PhD Boston Consulting Group Insilico Medicine Alex Zhavoronkov, PhD (aka Aleksandrs Zavoronkovs) Longevity Education Team Nir Barzilai Joan Mannick, the Co-Founder and CEO of Tornado Therapeutics talks about longevity medicine therapeutics, applied geroprotective interventions and rapalogs #ardd 2023 #ardd
Co-chair Justin Eyquem UCSF Helen Diller Family Comprehensive Cancer Ctr reviews synthetic immunology to build better CARs Society for Immunotherapy of Cancer Adding or removing ITAMs, inserting JAK3/STAT3/STAT5, another CD3z, Rapalogs, SNIP, synNotch can modulate function. Can also rest cells with Dasatinib to block tonic signaling. #CIWS23
Daniel Gilbert Here is a interesting episode about research on rapamycin, rapalogs and other mTOR inhibitors.
youtu.be/f1b4sxLQD08?si…
Aleksey Belikov Krister Kauppi - Longevity Lifestyle Hacker Great questions!
1. mTOR inhibition extends lifespan. The top hit is an mTOR inhibitor (just not rapa).
2. Rapa and rapalogs have very poor solubility that prevents testing high doses reported to extend in literature.
Here's a discussion: youtu.be/eedfbvCWq0k?fe…
Agingdoc⭐David Barzilai🔔MD PhD MS MBA DipABLM🩺 Mikhail V. Blagosklonny, MD, PhD Interesting summary, but still on the fence with rapamycin. Scheduling gets even more complicated with rapalogs (ad pubs.acs.org/doi/10.1021/ac…)...this is where the layman gives up and patiently waits for trials to progress...
Here is a systematic review of all the evidence on rapamycin and rapalogs
thelancet.com/journals/lanhl… The Lancet Healthy Longevity